Beam Therapeutics, Inc. (BEAM)
20.90
-0.04
(-0.19%)
USD |
NASDAQ |
Nov 20, 16:00
21.03
+0.13
(+0.62%)
After-Hours: 20:00
Beam Therapeutics Research and Development Expense (TTM) : 409.00M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 409.00M |
| June 30, 2026 | 408.66M |
| March 31, 2026 | 415.33M |
| December 31, 2025 | 409.62M |
| September 30, 2025 | 411.79M |
| June 30, 2025 | 396.28M |
| March 31, 2025 | 381.56M |
| December 31, 2024 | 367.56M |
| September 30, 2024 | 406.19M |
| June 30, 2024 | 411.99M |
| March 31, 2024 | 422.55M |
| December 31, 2023 | 437.38M |
| September 30, 2023 | 383.64M |
| June 30, 2023 | 368.88M |
| March 31, 2023 | 345.83M |
| Date | Value |
|---|---|
| December 31, 2022 | 311.59M |
| September 30, 2022 | 322.03M |
| June 30, 2022 | 291.37M |
| March 31, 2022 | 262.39M |
| December 31, 2021 | 387.09M |
| September 30, 2021 | 322.76M |
| June 30, 2021 | 297.96M |
| March 31, 2021 | 271.74M |
| December 31, 2020 | 103.18M |
| September 30, 2020 | 90.94M |
| June 30, 2020 | 73.66M |
| March 31, 2020 | 66.99M |
| December 31, 2019 | 54.62M |
| September 30, 2019 | 44.25M |
| June 30, 2019 | 41.56M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Intellia Therapeutics, Inc. | 326.72M |
| Twist Bioscience Corp. | 71.84M |
| Sarepta Therapeutics, Inc. | 647.26M |
| Prime Medicine, Inc. | 136.33M |
| Q32 Bio, Inc. | 15.94M |